Engy Risha

Prof. Dr. Engy Risha

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2015 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
MEMohamed El-Boshy
Mohamed El-Boshy
EREngy Risha
Engy Risha
FAFatma M. Abdelhamid
Fatma M. Abdelhamid
Mohammad MubarakMohammad Mubarak
Mohammad Mubarak
THTaibi Ben Hadda
Taibi Ben Hadda

1 April 2018 in Aquatic Toxicology
Verified
Journal Article
Closed access
Eman ZahranEman Zahran
Eman Zahran
EREngy Risha
Engy Risha
WAWalaa Awadin
Walaa Awadin
DPDušan Palić
Dušan Palić

1 September 2018 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
Eman ZahranEman Zahran
Eman Zahran
EEEman A. Abd El-Gawad
Eman A. Abd El-Gawad
EREngy Risha
Engy Risha


16 May 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
DRDoha Reda
Doha Reda
Gehad E. ElshopakeyGehad E. Elshopakey
Gehad E. Elshopakey
TATalat A. Albukhari
Talat A. Albukhari
SASamah J Almehmadi
Samah J Almehmadi
Bassem RefaatBassem Refaat
Bassem Refaat
FAFatma M. Abdelhamid
Fatma M. Abdelhamid
Introduction: Nonalcoholic fatty liver disease (NAFLD) is a chronic disease characterized by fat deposits in liver cells, which can lead to hepatitis and fibrosis. This study attempted to explore the protective effect of vitamin D3 (VitD) against NAFLD.Methods: Adult male albino rats were randomized into four separate groups: the negative control group was fed a standard rat chow; the positive group received a high-fat diet (20%) and 25% fructose water (NAFLD); the VitD control group was intramuscularly treated with VitD (1,000 IU/kg BW) 3 days per week for 10 weeks; and the NAFLD group was treated with VitD therapy. Biochemical and hepatic histological analyses were performed. Hepatic oxidative stress and inflammatory conditions were also studied. Hepatic expression of sterol regulatory element-binding protein 1-c (SREBP-1-c), peroxisome proliferator-activated receptor alpha (PPAR-α), and insulin receptor substrate-2 was analyzed by quantitative real-time polymerase chain reaction.Results and discussion: The NAFLD rats exhibited elevated terminal body weight, hepatic injury markers, dyslipidemia, glucose intolerance, and insulin resistance. Moreover, the NAFLD rats had increased SREBP-1-c expression and reduced PPAR-α and IRS-2 expressions. Histological analysis showed hepatic steatosis and inflammation in the NAFLD group. In contrast, VitD administration improved the serum biochemical parameters and hepatic redox status in NAFLD rats. Also, VitD treatment ameliorated hepatic inflammation and steatosis in the NAFLD group by decreasing the expression of SREBP-1-c and increasing the expression of PPAR-α. Overall, these results suggest that VitD could have a protective effect against NAFLD and its associated complication.